[ad_1] Astrazeneca Saphnelo approved in EU for subcutaneous self-administration for systemic lupus erythematosus adults We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] AstraZeneca Saphnelo subcutaneous self-administration recommended for approval in EU by CHMP for systemic lupus erythematosus We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] AstraZeneca’s hopes of a big new indication for respiratory drug Fasenra in chronic obstructive pulmonary disease (COPD) have been dashed by a negative phase 3 trial. The RESOLUTE study of IL-5 inhibitor Fasenra (benralizumab) showed some improvement with Fasenra compared to placebo in reducing COPD exacerbations, or attacks, that signal progression of the debilitating…